Results 181 to 190 of about 49,984 (235)

Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus: A Cross‐Sectional Population‐Based Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7312-7320, August 2026.
ABSTRACT Aims Chronic kidney disease (CKD) is a common complication of Type 2 diabetes that frequently co‐occurs with cardiovascular disease. We aimed to characterise CKD in adults with Type 2 diabetes, quantify its prevalence across severity levels and examine pharmacological treatment patterns and healthcare utilisation.
Neora Alterman, Yoel Toledano, Noga Fallach, Victor Gross, Galia Zacay   +4 more
wiley   +1 more source

Trials evaluating nicorandil renoprotection against contrast-induced nephropathy after coronary angiography or percutaneous coronary intervention: a systematic review and meta-analysis. [PDF]

Egypt Heart J
Ferreira NL, Aguiar DR, Nair SG, Shehab MA, Adelowo AB, Damirchi MR, Jones D, Rathod K, Khan Z.   +8 more
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7367-7379, August 2026.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Association of triglyceride-glucose index and high-sensitivity C-reactive protein with contrast-induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome: a retrospective cohort study. [PDF]

Front Cardiovasc Med
Tian G, Qian C, Liu Z, Xu Y, Yang L, He L.   +5 more
europepmc   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7416-7429, August 2026.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

The relationship between the Fibrosis-4 (FIB-4) index, occurrence of contrast-induced nephropathy, and prognosis after percutaneous coronary intervention in acute coronary syndromes. [PDF]

Postepy Kardiol Interwencyjnej
Sielski J, Kaziród-Wolski K, Piotrowska AM, Salwa K, Merchel L, Jurczak B, Klasa A, Kozieł K, Ludew M, Maj F, Pytlak K, Siudak Z.   +11 more
europepmc   +1 more source

Glomerular plasmalemma vesicle‐associated protein‐1 as an endothelial remodelling marker complementing C4d in chronic active antibody‐mediated rejection

Histopathology, Volume 89, Issue 2, Page 372-382, August 2026.
Glomerular plasmalemma vesicle‐associated protein‐1 (PV‐1/PLVAP) identifies dynamic endothelial remodelling in chronic active antibody‐mediated rejection (caABMR), complementing glomerular C4d, which reflects a static footprint of complement activation. Combined assessment of PV‐1 and C4d captures complementary dimensions of microvascular pathology and
Yuto Igarashi, Mayu Shimokawa, Kunio Kawanishi, Toshihito Hirai, Hiroshi Seino, Tomokazu Shimizu, Hideki Ishida, Toshio Takagi   +7 more
wiley   +1 more source

Diagnostic Value of Sirtuin-1 in Predicting Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. [PDF]

J Clin Med
Ardic M, Gul CB.
europepmc   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1322-1334, August 2026.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source